Clozapine use by state programs: public mental health systems respond to a new medication.
Clozapine use by state programs: public mental health systems respond to a new medication.
复制标题
国家计划使用氯氮平：公共心理健康系统对新药物做出反应。
DOI：
--
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
W. Rago
中科院分区：
文献类型：
--
作者：
W. Reid;V. Pham;W. Rago
作者提供了对州精神卫生部门进行的一项全国调查的数据，显示在进入美国市场两年后，氯氮平仅可供一小部分可能受益的患者使用。大多数精神分裂症患者得到护理的公共部门面临的主要持续障碍是资金。有几个论点支持在州精神卫生系统中使用氯氮平：对于许多患者来说，它是最有效或唯一有效的药物，它可以降低精神分裂症和相关疾病的巨大费用，并且获得药物已成为倡导团体和其他精神健康活动家的一个重要问题。德克萨斯州精神卫生系统两年的氯氮平使用经验表明，社区中氯氮平的可用性是医院成功使用该药物的重要因素。作者讨论了鼓励门诊氯氮平项目的方法，这对于医院和社区的成功治疗至关重要。
The authors present data from a national survey of state departments of mental health showing that two years after reaching the U.S. market, clozapine is available to only a small fraction of the patients whom it might benefit. The primary continuing hurdle for the public sector, where most schizophrenic patients get their care, is funding. Several arguments support the use of clozapine in state mental health systems: it is the most effective or only effective medication for many patients, it can decrease the enormous costs of schizophrenia and related disorders, and access to the medication has become an important issue for advocacy groups and other mental health activists. Two years of experience with clozapine in the Texas mental health system have shown that availability of clozapine in the community is a vital factor for successful use of the drug in hospitals. The authors discuss ways to encourage outpatient clozapine programs that are critical to successful treatment in both the hospital and the community.